Since XIAP knockdown negatively impaired tumor growth of NEC-DUE cell lines in vivo, we took advantage of the well characterized smac mimetics Birinapant and GDC-0152 that have been demonstrated to selectively antagonize IAPs. Here, XIAP is linked to neuroendocrine carcinoma.